半岛·综合体育官网(中国)入口NO.1

05, 1972Tai county pharmaceutical factory was established

July 1982LVP won the fifth place in the provincial quality evaluation of 58 same industry

05, 1989Obtained the new drug certificate of zhichuanling injection and the production approval document, and became the first TCM compound injection approved for production after the implementation of the drug administration law and the new drug approval measures in China (the first TCM compound injection registered in the Chinese pharmacopoeia).

In March 1991Zhichuanling injection and weining granule won the silver award of international exposition

01, 2000Take the lead in establishing the key enterprise technology center of jiangsu province

In October 2000The workshop is the first to pass the GMP certification nationwide

02, 2002In the overall restructuring, jiangsu suzhong pharmaceutical co., LTD was established, and jiangsu suzhong haixin pharmaceutical co., LTD was established, and the production workshop was built according to the eu GMP standard

05, 200230th anniversary celebration

In October 2002Establish a national post-doctoral research station

In November 2003Nanjing suzhong pharmaceutical research co., LTD

02, 2004Introduce ERP, yonyou management system

The year in 2006For the first time, it ranks among the top 100 pharmaceutical industry in China

01, 2012"Su zhong" trademark won China's well-known trademark

05, 201240th anniversary celebration

04, 2013Sino-french business BBS invited suyao group to attend the conference, and huangkui capsule became the only international cooperation project of traditional Chinese medicine approved by the French government

In December 2013It has built the first digital production workshop of TCM injections in China

In December 2014Carry out sino-french cooperation project on huangkui capsules

In December 2016Huangkui capsule won the first prize of national science and technology progress

05, 2018Group research institute opening ceremony jinan research institute relocation ceremony was held

In October 2018Ambrette capsule Ⅳ period clinical research was published IgA nephropathy - the world's largest sample of multicenter, randomized, double blind and double simulation and control study confirmed that ambrette capsule reducing CKD1-3 a period of IgA nephropathy urine protein function is not inferior to potassium chloride sand jotham 100 mg/d; Moreover, patients with urinary protein ≥2.0g/d were superior to losartan potassium -- the highest grade A evidence in the RCT study